Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
Parkinson's disease
multiple system atrophy
neuromelanin-sensitive imaging
progressive supranuclear palsy
substantia nigra degeneration
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
15
02
2022
received:
01
11
2021
accepted:
17
02
2022
pubmed:
30
3
2022
medline:
18
6
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
Neurodegeneration in the substantia nigra pars compacta (SNc) in parkinsonian syndromes may affect the nigral territories differently. The objective of this study was to investigate the regional selectivity of neurodegenerative changes in the SNc in patients with Parkinson's disease (PD) and atypical parkinsonism using neuromelanin-sensitive magnetic resonance imaging (MRI). A total of 22 healthy controls (HC), 38 patients with PD, 22 patients with progressive supranuclear palsy (PSP), 20 patients with multiple system atrophy (MSA, 13 with the parkinsonian variant, 7 with the cerebellar variant), 7 patients with dementia with Lewy body (DLB), and 4 patients with corticobasal syndrome were analyzed. volume and signal-to-noise ratio (SNR) values of the SNc were derived from neuromelanin-sensitive MRI in the whole SNc. Analysis of signal changes was performed in the sensorimotor, associative, and limbic territories of the SNc. SNc volume and corrected volume were significantly reduced in PD, PSP, and MSA versus HC. Patients with PSP had lower volume, corrected volume, SNR, and contrast-to-noise ratio than HC and patients with PD and MSA. Patients with PSP had greater SNR reduction in the associative region than HC and patients with PD and MSA. Patients with PD had reduced SNR in the sensorimotor territory, unlike patients with PSP. Patients with MSA did not differ from patients with PD. This study provides the first MRI comparison of the topography of neuromelanin changes in parkinsonism. The spatial pattern of changes differed between PSP and synucleinopathies. These nigral topographical differences are consistent with the topography of the extranigral involvement in parkinsonian syndromes. © 2022 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Neurodegeneration in the substantia nigra pars compacta (SNc) in parkinsonian syndromes may affect the nigral territories differently.
OBJECTIVE
The objective of this study was to investigate the regional selectivity of neurodegenerative changes in the SNc in patients with Parkinson's disease (PD) and atypical parkinsonism using neuromelanin-sensitive magnetic resonance imaging (MRI).
METHODS
A total of 22 healthy controls (HC), 38 patients with PD, 22 patients with progressive supranuclear palsy (PSP), 20 patients with multiple system atrophy (MSA, 13 with the parkinsonian variant, 7 with the cerebellar variant), 7 patients with dementia with Lewy body (DLB), and 4 patients with corticobasal syndrome were analyzed. volume and signal-to-noise ratio (SNR) values of the SNc were derived from neuromelanin-sensitive MRI in the whole SNc. Analysis of signal changes was performed in the sensorimotor, associative, and limbic territories of the SNc.
RESULTS
SNc volume and corrected volume were significantly reduced in PD, PSP, and MSA versus HC. Patients with PSP had lower volume, corrected volume, SNR, and contrast-to-noise ratio than HC and patients with PD and MSA. Patients with PSP had greater SNR reduction in the associative region than HC and patients with PD and MSA. Patients with PD had reduced SNR in the sensorimotor territory, unlike patients with PSP. Patients with MSA did not differ from patients with PD.
CONCLUSIONS
This study provides the first MRI comparison of the topography of neuromelanin changes in parkinsonism. The spatial pattern of changes differed between PSP and synucleinopathies. These nigral topographical differences are consistent with the topography of the extranigral involvement in parkinsonian syndromes. © 2022 International Parkinson and Movement Disorder Society.
Substances chimiques
Melanins
0
neuromelanin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1245-1255Informations de copyright
© 2022 International Parkinson and Movement Disorder Society.
Références
Dickson DW. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2012;2:a009258.
Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord 2018;46((suppl 1)):S30-S33.
Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU. The differential diagnosis and treatment of atypical parkinsonism. Dtsch Arzteblatt Int 2016;113:61-69.
Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain J Neurol 1991;114(Pt 5)):2283-2301.
Cassidy CM, Zucca FA, Girgis RR, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci U S A 2019;116:5108-5117.
Kitao S, Matsusue E, Fujii S, et al. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies. Neuroradiology 2013;55:947-953.
Pyatigorskaya N, Gaurav R, Arnaldi D, et al. Magnetic resonance imaging biomarkers to assess substantia Nigra damage in idiopathic rapid eye movement sleep behavior disorder. Sleep 2017;40. https://doi.org/10.1093/sleep/zsx149
Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17:1215-1218.
Gaurav R, Yahia-Cherif L, Pyatigorskaya N, et al. Longitudinal changes in Neuromelanin MRI signal in Parkinson's disease: a progression marker. Mov Disord 2021;36(7):1592-1602.
Biondetti E, Gaurav R, Yahia-Cherif L, et al. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease. Brain 2020;143(9):2757-2770.
Cho SJ, Bae YJ, Kim J-M, et al. Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis. Eur Radiol 2021;31:1268-1280.
Kashihara K, Shinya T, Higaki F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern Med 2011;50:1683-1687.
Ohtsuka C, Sasaki M, Konno K, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014;20:755-760.
Pyatigorskaya N, Yahia-Cherif L, Gaurav R, et al. Multimodal magnetic resonance imaging quantification of brain changes in progressive supranuclear palsy. Mov Disord 2020;35:161-170.
Taniguchi D, Hatano T, Kamagata K, et al. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease: Neuromelanin-MRI and midbrain Volumetry. Mov Disord 2018;33:1488-1492.
Matsuura K, Ii Y, Maeda M, et al. Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia. Parkinsonism Relat Disord 2021;87:75-81.
Matsuura K, Maeda M, Yata K, et al. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy. Eur Neurol 2013;70:70-77.
Simões RM, Castro Caldas A, Grilo J, et al. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. BMC Neurol 2020;20:432
Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. J Neurol 1999;122(Pt 8):1421-1436.
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591-1601.
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 2017;32:853-864.
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology 2017;89:88-100.
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496-503.
Mueller C, Hussl A, Krismer F, et al. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism Relat Disord 2018;54:90-94.
Möller L, Kassubek J, Südmeyer M, et al. Manual MRI morphometry in parkinsonian syndromes. Mov Disord 2017;32:778-782.
Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246:214-221.
Bajaj S, Krismer F, Palma J-A, et al. Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: a systematic review and meta-analysis. PloS One 2017;12:e0189897
Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain J Neurol 2002;125:1070-1083.
Quattrone A, Antonini A, Vaillancourt DE, et al. A new MRI measure to early differentiate progressive Supranuclear palsy from De novo Parkinson's disease in clinical practice: an international study. Mov Disord 2021;36:681-689.
Ourselin S, Roche A, Subsol G, Pennec X, Ayache N. Reconstructing a 3D structure from serial histological sections. Image Vis Comput 2001;19:25-31.
Modat M, Ridgway GR, Taylor ZA, et al. Fast free-form deformation using graphics processing units. Comput Methods Programs Biomed 2010;98:278-284.
Biondetti E, Santin MD, Valabrègue R, et al. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. Brain 2021;144(10):3114-3125.
Zhang Y, Larcher KM, Misic B, Dagher A. Anatomical and functional organization of the human substantia nigra and its connections. eLife 2017;6:e26653.
Prange S, Danaila T, Laurencin C, et al. Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology 2019;92:e148-e160.
Zecca L, Stroppolo A, Gatti A, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A 2004;101:9843-9848.
Xing Y, Sapuan A, Dineen RA, Auer DP. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Mov Disord 2018;33:1792-1799.
Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed Mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987;7(12):3915-3934.
Haber SN. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 2014;282:248-257.
Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
Jellinger K, Danielczyk W. Striato-nigrale degeneration. Acta Neuropathol 1968;10(3):242-257. https://doi.org/10.1007/BF00687726
Haber SN. The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 2003;26:317-330.
Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
Langley J, Huddleston DE, Merritt M, et al. Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited. Hum Brain Mapp 2016;37:2547-2556.
Burciu RG, Ofori E, Archer DB, et al. Progression marker of Parkinson's disease: a 4-year multi-site imaging study. Brain J Neurol 2017;140:2183-2192.
Andrews JM. Striatonigral degeneration: clinical-pathological correlations and response to stereotaxic surgery. Arch Neurol 1970;23:319
Bannister R, Gibson W, Michaels L, Oppenheimer DR. Laryngeal abductor paralysis in multiple system atrophy: a report on three necropsied cases, with observations on the laryngeal muscles and the nuclei ambigui. Brain 1981;104:351-368. https://pubmed.ncbi.nlm.nih.gov/7237099/
Sung JH, Mastri A, Segal E. Pathology of Shy-Drager syndrome. J Neuropathol Exp Neurol 1979;38(4):353
Borit A, Rubinstein L, Urich H. The striatonigral degenerations: putaminal pigments and nosology. Brain 1975;98(1):101-112.
Rajput AH, Kazi KH, Rozdilsky B. Striatonigral degeneration response to levodopa therapy. J Neurol Sci 1972;16:331-341.
Dickson DW, Lin W, Liu W-K, Yen S-H. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 1999;9:721-732.
Chougar L, Pyatigorskaya N, Degos B, Grabli D, Lehéricy S. The role of magnetic resonance imaging for the diagnosis of atypical parkinsonism. Front Neurol 2020;11:665
Pellecchia MT, Barone P, Vicidomini C, et al. Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov Disord 2011;26:1303-1309.
Tsukamoto K, Matsusue E, Kanasaki Y, et al. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. Neuroradiology 2012;54:947-955.
Meyer PT, Frings L, Rücker G, Hellwig S. 18F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 2017;58:1888-1898.
Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
Kim Y, Kim J-M, Kim J-W, et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean? Mov Disord 2002;17:568-575.
Ofori E, Krismer F, Burciu RG, et al. Free water improves detection of changes in the substantia nigra in parkinsonism: a multisite study. Mov Disord 2017;32:1457-1464.
Porrino LJ, Goldman-Rakic PS. Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP. J Comp Neurol 1982;205:63-76.
Lehéricy S, Hartmann A, Lannuzel A, et al. Magnetic resonance imaging lesion pattern in Guadeloupean parkinsonism is distinct from progressive supranuclear palsy. Brain J Neurol. 2010;133:2410-2425.
Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol 2018;17:618-628.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
Franzmeier N, Neitzel J, Rubinski A, et al. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. Nat Commun 2020;11:347
Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in non-transgenic mice. Science 2012;338:949-953.
Borghammer P. How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov Disord 2018;33:48-57.
Pandya S, Zeighami Y, Freeze B, et al. Predictive model of spread of Parkinson's pathology using network diffusion. Neuroimage 2019;192:178-194.
Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain J Neurol 2007;130:1566-1576.
Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol (Berl) 2008;116:1-16.
Jellinger KA. Formation and development of Lewy pathology: a critical update. J Neurol 2009;256(suppl 3)):270-279.
Ogisu K, Kudo K, Sasaki M, et al. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Neuroradiology 2013;55:719-724.
Liu XL, Yang LQ, Liu FT, et al. Short-echo-time magnitude image derived from quantitative susceptibility mapping could resemble neuromelanin-sensitive MRI image in substantia nigra. BMC Neurol 2020;20:262
Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011;26:1633-1638.